Products
Platform
Research
Market
Learn
Compare Kotak Healthcare Fund vs SBI Healthcare Opportunities Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 2.4 | 1.93 |
NAV | ₹13.68 | ₹435.75 |
Fund Started | 20 Nov 2023 | 04 Jun 1999 |
Fund Size | ₹464.13 Cr | ₹3933.26 Cr |
Exit Load | 0.5% for redemption within 30 Days | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹500
Expense Ratio
2.4
1.93
NAV
₹13.68
₹435.75
Fund Started
20 Nov 2023
04 Jun 1999
Fund Size
₹464.13 Cr
₹3933.26 Cr
Exit Load
0.5% for redemption within 30 Days
Exit load of 0.50% if redeemed within 15 days
Returns
1 Year | -1.66% | 3.00% |
3 Year | - | 25.65% |
5 Year | - | 19.35% |
1 Year
-1.66%
3.00%
3 Year
-
25.65%
5 Year
-
19.35%
Holding Analysis
Equity | 97.68% | 96.36% |
Cash | 2.32% | 3.56% |
Equity
97.68%
96.36%
Cash
2.32%
3.56%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.05% |
Max Healthcare Institute Ltd. | 7.33% |
JB Chemicals & Pharmaceuticals Ltd. | 5.93% |
Cipla Ltd. | 5.51% |
Divi's Laboratories Ltd. | 4.90% |
Apollo Hospitals Enterprise Ltd. | 4.23% |
Fortis Healthcare Ltd. | 4.18% |
Lupin Ltd. | 3.91% |
Jubilant Pharmova Ltd. | 3.26% |
Krishna Institute of Medical Sciences Ltd | 3.02% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.94% |
Divi's Laboratories Ltd. | 6.36% |
Max Healthcare Institute Ltd. | 5.67% |
Cipla Ltd. | 4.59% |
Lupin Ltd. | 4.08% |
Lonza Group Ag | 4.06% |
Fortis Healthcare Ltd. | 3.70% |
Torrent Pharmaceuticals Ltd. | 3.66% |
Gland Pharma Ltd. | 3.54% |
Mankind Pharma Ltd. | 3.34% |
Fund Manager
Name | Shibani Sircar Kurian | Tanmaya Desai |
Start Date | 12 Feb 2024 | 17 May 2024 |
Name
Shibani Sircar Kurian
Tanmaya Desai
Start Date
12 Feb 2024
17 May 2024
About Fund
Description | The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 20 Nov 2023 | 04 Jun 1999 |
Description
The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
20 Nov 2023
04 Jun 1999